FDA Approves Innovative Biological Treatment for Advanced Head and Neck Cancer
The FDA approved a breakthrough biological treatment for advanced head and neck cancer, achieving tumor reduction in 45 percent of patients where prior therapies failed.

A groundbreaking biological treatment has received approval from the US Food and Drug Administration (FDA) to treat advanced head and neck cancer, offering new hope after more than a decade of limited medical options. Clinical trials demonstrated a significant tumor reduction in approximately 45 percent of participating patients, even after all prior conventional therapies had failed.
Dual-Target Attack Mechanism
Until now, biological treatments typically attempted to block only a single escape route used by cancerous cells, allowing the disease to adapt and continue spreading. The new therapy operates on a dual-attack principle, simultaneously neutralizing two critical tumor growth proteins known as EGFR and MET. Professor Aaron Popovtzer, director of the Sharett Institute of Oncology at the Hadassah Hebrew University Medical Center, explained that this dual mechanism prevents tumors from evading treatment.
"This is a major innovation in the field."
Restoring Quality of Life
Beyond extending life expectancy, the treatment restores fundamental human functions such as swallowing, eating, speaking, and breathing. As the biological therapy shrinks the tumor, pressure on vital organs and airways decreases, directly improving the patient's daily routine and overall well-being. While the therapy may cause side effects such as skin rashes, modern medical protocols effectively manage and minimize them through preventative care.
The new treatment is specifically intended for adult patients with recurrent or metastatic head and neck cancer who have not responded to immunotherapy. Because the medication is already utilized in Israel for other oncological conditions, medical experts anticipate its integration into the national health basket for this new indication, potentially benefiting dozens of patients annually.





